Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

Last updated: November 16, 2016
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Stress

Vascular Diseases

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT00353912
CVAA489A2402
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years of age or older.

  • Moderate to severe high blood pressure. This is defined as a systolic pressure (thetop number) greater than or equal to 160 mmHg and less than 200 mmHg.

Exclusion

Exclusion Criteria:

  • History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics

  • Inability to stop all prior blood pressure medications safely

  • Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg

  • Controlled blood pressure (systolic BP < 140 mmHg) taking more than 3 antihypertensivemedications at screening

  • Systolic BP ≥ 140 mmHg and < 180 mmHg taking more than two antihypertensivemedications at screening

  • Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening

  • History of autoimmune diseases

  • History of multiple drug allergies

  • Liver disease

  • Pancreatic injury within 1 year of screening

  • Evidence of kidney impairment or history of dialysis

  • Any surgical or medical condition which might alter the absorption, distribution,metabolism, or excretion of any drug. This could include currently active gastritis,ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.

  • Women of child-bearing potential (WOCBP), defined as all women physiologically capableof becoming pregnant, would be excluded UNLESS they are post-menopausal, surgicallysterile OR are using acceptable methods of contraception. The use of hormonalcontraceptives is not allowed

  • Pregnant or nursing (lactating) women

  • History of malignancy of any organ system within the past five years

  • Any severe, life-threatening disease within the past five years

  • History of drug or alcohol abuse within the last 2 years.

  • History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack orunstable angina

  • Type 1 diabetes

  • Poorly controlled Type 2 diabetes

  • History of heart failure

  • Arrhythmia

  • Significant valvular heart disease

  • Active gout Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Total Participants: 571
Study Start date:
June 01, 2006
Estimated Completion Date:
April 30, 2007

Connect with a study center

  • Novartis Pharmaceuticals

    E. Hanover, New Jersey 07936
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.